Pictet Asset Management Holding SA Has $2.60 Million Stock Position in Tempus AI, Inc. $TEM

Pictet Asset Management Holding SA grew its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 24.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,468 shares of the company’s stock after acquiring an additional 11,980 shares during the period. Pictet Asset Management Holding SA’s holdings in Tempus AI were worth $2,603,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. JPL Wealth Management LLC bought a new position in shares of Tempus AI during the third quarter worth approximately $26,000. Los Angeles Capital Management LLC bought a new stake in Tempus AI in the 4th quarter valued at $27,000. Harvest Fund Management Co. Ltd bought a new stake in Tempus AI in the 3rd quarter valued at $38,000. Danske Bank A S acquired a new position in Tempus AI in the 3rd quarter valued at $48,000. Finally, Sunbelt Securities Inc. acquired a new position in Tempus AI in the 3rd quarter valued at $52,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $60.27 on Monday. The business has a fifty day moving average price of $50.48 and a two-hundred day moving average price of $54.47. The stock has a market capitalization of $10.82 billion, a PE ratio of -35.04 and a beta of 3.46. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The company had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.Tempus AI’s revenue was up 36.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.24) earnings per share. As a group, equities analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Ryan M. Bartolucci sold 4,116 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $181,392.12. Following the completion of the sale, the chief accounting officer owned 74,041 shares of the company’s stock, valued at approximately $3,262,986.87. This represents a 5.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James William Rogers sold 11,529 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00. Following the sale, the chief financial officer owned 114,866 shares in the company, valued at $6,317,630. This represents a 9.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 572,759 shares of company stock valued at $29,238,424. Company insiders own 24.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on TEM. Wall Street Zen downgraded Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright decreased their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research report on Wednesday, June 17th. BTIG Research reiterated a “buy” rating and issued a $80.00 price objective on shares of Tempus AI in a research note on Monday, June 1st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a report on Monday, June 1st. Nine analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $68.54.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.